Ixekizumab is superior to placebo for the treatment of nail, scalp, and palmoplantar psoriasis in pediatric patients with moderate to severe plaque psoriasis

被引：0
|
作者：
Paller, Amy S. [1 ]
Magarinos, Gabriel Alejandro [1 ]
Pinter, Andreas [1 ]
Cather, Jennifer [1 ]
Keller, Stuart [1 ]
Capriles, Claudia Rodriguez [1 ]
Gallo, Gaia [1 ]
Edson-Heredia, Emily [1 ]
Li, Lingnan [1 ]
Papp, Kim [1 ]
机构：
[1] Northwestern Med, Chicago, IL USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
14161
引用
收藏
页码：AB20 / AB20
页数：1
相关论文
共 50 条
  • [1] Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis
    Cather, Jennifer Clay
    Young, Chaney T.
    Young, Melody S.
    Cather, J. Christian
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (08) : 983 - 990
  • [2] Palmoplantar psoriasis complete clearance is achieved rapidly and sustained with ixekizumab treatment in adult and pediatric patients with moderate-to-severe plaque psoriasis
    Menter, Martin Alan
    Armstrong, April
    Kircik, Leon
    Gniadecki, Robert
    Garrelts, Alyssa
    See, Kyoungah
    McKean-Matthews, Missy
    Bagel, Jerry
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB203 - AB203
  • [3] Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate-to-severe psoriasis
    Augustin, Matthias
    Mrowietz, Ulrich
    Willsmann-Theis, Dagmar
    Gerdes, Sascha
    Fotiou, Konstantinos
    Schuster, Christopher
    Mert, Can
    Holzkaemper, Thorsten
    Behrens, Frank
    Pinter, Andreas
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2024,
  • [4] Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis
    Crowley, Jeffrey
    Gooderham, Melinda
    Richter, Sven
    Shi, Rebecca
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB62 - AB62
  • [5] Efficacy and Safety of Ixekizumab in Pediatric Patients with Moderate-to-Severe Plaque Psoriasis
    Paller, Amy
    Seyger, Marieke
    Alejandro Magarinos, Gabriel
    Bagel, Jerry
    Keller, Stuart
    Capriles, Claudia Rodriguez
    Gallo, Gaia
    Edson-Heredia, Emily
    Li, Lingnan
    Xu, Wen
    Papp, Kim
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 17 - 17
  • [6] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Syed, Yahiya Y.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2017, 18 (01) : 147 - 158
  • [7] Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis
    Yahiya Y. Syed
    American Journal of Clinical Dermatology, 2017, 18 : 147 - 158
  • [8] Nail psoriasis as a predictor of skin response to ixekizumab in patients with moderate-to-severe psoriasis
    Rich, P.
    Goldblum, O.
    Amato, D.
    Disch, D.
    Muram, D.
    Merola, J. F.
    Elewski, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S67 - S67
  • [9] Apremilast in moderate to severe plaque psoriasis: 32-week results in patients with nail, scalp, and palmoplantar involvement (ESTEEM 2)
    Sebastian, M.
    Crowley, J.
    Cather, J.
    Gooderham, M.
    Girolomoni, G.
    Ferrandiz, C.
    Hu, C. C.
    Day, R.
    Beylot-Barry, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2015, 13 : 94 - 95
  • [10] Effect of ixekizumab treatment on scalp psoriasis: Results from a phase 2 study in patients with moderate to severe psoriasis
    Langley, Richard
    Zhu, Baojin
    Leonardi, Craig
    Edson-Heredia, Emily
    Cameron, Gregory
    Erickson, Janelle
    Heffernan, Michael
    Maeda-Chubachi, Tomoko
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB168 - AB168
12345